CBIO vs LCTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Options & Structure while CBIO counters with relative strength in Momentum & Technical. Fundamentally, CBIO trades at N/M Forward P/E with -1228.4% operating margin (+0.0% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CBIO Revenue | LCTX Revenue | CBIO Op. Margin | LCTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -837.9% | LCTX |
| FY2019 | N/A | $0M | N/A | -1106.0% | LCTX |
| FY2020 | $10M | $0M | -506.8% | -1448.4% | CBIO |
| FY2021 | $0M | $0M | -5470.7% | -1133.6% | LCTX |
| FY2022 | $0M | $10M | -63204.4% | -153.2% | LCTX |
| FY2023 | $0M | $10M | -392752.9% | -276.5% | LCTX |
| FY2024 | N/A | $10M | N/A | -226.1% | LCTX |
| FY2025 | $10M | $10M | -1407.5% | -251.6% | LCTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CBIO | LCTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $539.5M | $207.4M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | +0.0% | -61.0% | Higher Growth | CBIO |
| Operating Margin (TTM) Profitability | -1228.4% | -280.3% | Higher Margin | LCTX |
| Net Profit Margin Profitability | 0.0% | 16.2% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | -160.8% | 4.3% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 23% ($9โ$27) | 0% ($1โ$2) | Stronger Trend | CBIO |
| Beta / 30D Volatility Risk Regime | 1.18ฮฒ ยท 60% Vol | 1.39ฮฒ ยท 79% Vol | Lower Realized Risk | CBIO |
| Unified Institutional Score Composite Signal | 49.2 / 100 (HOLD) | 54.9 / 100 (HOLD) | Higher Composite | LCTX |